May 19, 2021
Press Releases for Artiva Biotherapeutics
February 26, 2021
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
January 5, 2021
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
December 7, 2020
Artiva Biotherapeutics Announces FDA Allowance of IND to Initiate Clinical Trials of AB-101 in Combination with Rituximab for the Treatment of Advanced B-cell Lymphomas
June 26, 2020